Transjugular Intrahepatic Portosystemic Shunt Linked to Increased Risk of Hepatocellular Carcinoma:A VA Matched Cohort Study  

作　　者：Shalini Bansal Tamar Taddei Rebecca Wells Marina Serper Theresa Bittermann Nadim Mahmud David E.Kaplan 

机构地区：[1]Sidney Kimmel Medical College at Thomas Jefferson University,Philadelphia,PA,USA [2]Division of Gastroenterology and Hepatology Perelman School of Medicine,University of Pennsylvania,Philadelphia,PA,USA [3]Corporal Michael J.Crescenz VA Medical Center,Philadelphia,PA,USA [4]Division of Gastroenterology and Hepatology,Yale University School of Medicine,New Haven,CT,USA [5]VA Connecticut Healthcare System,West Haven,CT,USA

出　　处：《Journal of Clinical and Translational Hepatology》2024年第5期534-538,共5页临床与转化肝病杂志（英文版）

摘　　要：Hepatocellular carcinoma(HCC)is the most common primary tumor of the liver and often evolves from regenerating nodules in liver cirrhosis.While there have been significant advances in the treatment of HCC,the overall prognosis in patients with a large tumor burden,vascular invasion,or extrahepatic spread remains poor.1 The magnitude of liver stiffness in cirrhosis has been consistently associated with an increased risk of development of HCC.

关 键 词：CARCINOMA INVASION CIRRHOSIS 

分 类 号：R735.7[医药卫生—肿瘤]